Literature DB >> 1862203

Is there an alternative to the randomized controlled trial?

P Leber1.   

Abstract

The advantages of the concurrently randomized controlled trial as a device to assess the efficacy of drugs intended for use in the field of psychiatry are reviewed. The importance of "assay sensitivity" is discussed and illustrations of errors that can arise when inferences about efficacy are based upon comparisons that find no difference between experimental and standard treatments are presented. These illustrations are derived from data collected in two different pre-marketing commercial drug development programs. Also discussed is the argument that controlled trials are inappropriate devices to test drug efficacy because of their alleged lack of sensitivity to drug effects.

Mesh:

Substances:

Year:  1991        PMID: 1862203

Source DB:  PubMed          Journal:  Psychopharmacol Bull        ISSN: 0048-5764


  6 in total

Review 1.  Design of clinical trials of antidepressants: should a placebo control arm be included?

Authors:  J Fritze; H J Möller
Journal:  CNS Drugs       Date:  2001       Impact factor: 5.749

Review 2.  Placebos in clinical practice and research.

Authors:  P P De Deyn; R D'Hooge
Journal:  J Med Ethics       Date:  1996-06       Impact factor: 2.903

3.  The use of placebos in psychiatry: a response to the draft document prepared by the Tri-Council Working Group. Canadian College of Neuropsychopharmacology.

Authors:  S N Young; L Annable
Journal:  J Psychiatry Neurosci       Date:  1996-07       Impact factor: 6.186

Review 4.  Essential statistical principles of clinical trials of pain treatments.

Authors:  Robert H Dworkin; Scott R Evans; Omar Mbowe; Michael P McDermott
Journal:  Pain Rep       Date:  2020-12-18

5.  Prospective randomized trials affect the outcomes of intraabdominal infection.

Authors:  J I Merlino; M A Malangoni; C M Smith; R L Lange
Journal:  Ann Surg       Date:  2001-06       Impact factor: 12.969

6.  Placebo response in depression.

Authors:  Shamsah B Sonawalla; Jerrold F Rosenbaum
Journal:  Dialogues Clin Neurosci       Date:  2002-03       Impact factor: 5.986

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.